1059. Staphylococcus aureus bacteremia treatment: results from pilot surveillance in four US states.
Session: Poster Abstract Session: Bacteremia and Endocarditis
Friday, October 5, 2018
Room: S Poster Hall
Background: Staphylococcus aureus treatment guidelines are being revised to include proposed quality measures for evaluation of patients with S. aureus bacteremia (SAB) (e.g. infectious disease (ID) consultation, echocardiogram and documenting clearance of bacteremia). We describe current management practices of SAB to identify opportunities for quality improvement.

Methods: We conducted a pilot assessment of SAB cases reported to CDC’s Emerging Infections Program active, laboratory- and population-based surveillance from 24 hospitals in 4 states during 1-2 months in 2017 or 2018. A SAB case was the isolation of S. aureus from a blood culture among adults (≥ 18 years) in the catchment area. We collected clinical and demographic information and performed a descriptive analysis of management of SAB cases.

Results: Among 109 SAB cases identified, 50 (46%) were methicillin-resistant S. aureus (MRSA). While hospitalized, 87 (80%) patients were evaluated by ID consultation, 90 (83%) underwent an echocardiogram (26 were transesophageal), and 92 (84%) had documented clearance of bacteremia. During the hospitalization, 15 (14%) died and 12 (11%) left against medical advice (AMA). Of those who survived and did not leave AMA, median duration of hospitalization after initial culture was 10.5 days (interquartile range 7-18). In total, 10 survivors (9% of cases) completed at least two weeks of antibiotics while hospitalized, and 65 (60% of cases) were discharged on antibiotic therapy. Among the 25 MRSA patients discharged on antibiotics, common treatments were vancomycin (64%), daptomycin (8%), ceftaroline (8%) and linezolid (4%). Among the 40 methicillin-susceptible SAB patients discharged on antibiotics, cefazolin (56%), ceftriaxone (13%), cefepime (5%), linezolid (5%), nafcillin (3%) and vancomycin (3%) were most common. The remainder of outpatient treatments included oral β-lactams, clindamycin, doxycycline, levofloxacin and erythromycin.

Conclusion: Overall, the majority of patients with SAB underwent evaluation according to the proposed quality measures and received therapy with targeted anti-staphylococcal agents, although opportunities to optimize treatment remain. Hospitalized patients who leave AMA represent a particular challenge for effective SAB therapy.

Sarah Kabbani, MD MSc1, Kelly Jackson, MPH1, Lauren Epstein, MD, MSc1, Anita Gellert, RN2, Carmen Bernu, BS3, Rahsaan Overton, MPH4, Joelle Nadle, MPH5, Ghinwa Dumyati, MD, FSHEA6, Ruth Lynfield, MD, FIDSA3, Susan M. Ray, MD7, Erin Epson, MD8 and Isaac See, MD1, (1)Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA, (2)NY Emerging Infections Program, Center for Community Health and Prevention, University of Rochester Medical Center, Rochester, NY, (3)Minnesota Department of Health, St. Paul, MN, (4)Georgia Emerging Infections Program, Atlanta, GA, (5)California Emerging Infections Program, Oakland, CA, (6)University of Rochester Medical Center, Rochester, NY, (7)Emory University School of Medicine, Atlanta, GA, (8)Healthcare-Associated Infections Program, California Department of Public Health, Richmond, CA

Disclosures:

S. Kabbani, None

K. Jackson, None

L. Epstein, None

A. Gellert, None

C. Bernu, None

R. Overton, None

J. Nadle, None

G. Dumyati, None

R. Lynfield, None

S. M. Ray, None

E. Epson, None

I. See, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.